A Phase 3 interventional study of Walvax PCV13-TT and Pfizer PCV13 in Pneumococcal Disease, Invasive, sponsored by Walvax Biotechnology Co., Ltd.. Active, not recruiting at 2 sites in Indonesia. Open to participants aged 6 Weeks to 8 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-03.
Sponsored by Walvax Biotechnology Co., Ltd. · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to evaluate the immunogenicity and safety of a novel 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13-TT) as compared to Pfizer's 13-valent pneumococcal conjugate vaccine (PCV13) when co-administered with local EPI Vaccines at 2, 4, and 12-15 months of age, to healthy infants in Indonesia. This study aims to demonstrate the non-inferiority of the serotype-specific immune responses elicited by the novel PCV13-TT as compared to PCV13 one month after the booster dose.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
This study's enrollment of 630 is above the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Browse Pneumococcal Infections studies →Walvax Biotechnology Co., Ltd. is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Infants must meet ALL the following inclusion criteria for enrollment in the study, at the time of the screening:
Exclusion Criteria:
The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Primary Vaccination: A total of approximately 300 infants 6-8 weeks of age will be enrolled and assigned randomly to receive at 2, 4, and 12-15 months of age 1 dose of PCV13-TT. Standard EPI vaccines will be administered concomitantly. Booster Vaccination: At 12-15 months of age (8 to 11 months after the 2nd dose of the primary series), infants will receive a booster dose of PCV13-TT.
Biological: Walvax PCV13-TT
Primary Vaccination: A total of approximately 300 infants 6-8 weeks of age will be enrolled and assigned randomly to receive at 2, 4, and 12-15 months of age 1 dose of PCV13. Standard EPI vaccines will be administered concomitantly. Booster Vaccination: At 12-15 months of age (8 to 11 months after the 2nd dose of the primary series), infants will receive a booster dose of PCV13.
Biological: Pfizer PCV13
PCV13-TT is supplied as 0.5 mL prefill syringe (PFS), with 0.5 mL suspension for intramuscular injection. After shaking, the vaccine is a homogenous, white suspension. Each dose (0.5 mL) of PCV13-TT contains pneumococcal polysaccharide serotypes 1, 3 4, 5, 6A 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F which are conjugated to TT carrier protein individually. The vaccine is formulated in phosphate-buffered saline containing 4.25 mg/dose sodium chloride (NaCl), 44.35 μg/dose sodium dihydrogen phosphate (NaH2PO4), 19.0 μg/dose disodium hydrogen phosphate (Na2HPO4), and contains 0.5 mg/dose of aluminum phosphate as an adjuvant; no preservatives added.
PCV13 is a suspension for intramuscular injection available in 0.5 mL single-dose prefilled syringes. Each 0.5 mL dose of PCV13 is formulated to contain approximately 2.2 μg of each of S. pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F polysaccharides, 4.4 μg of 6B polysaccharides, 34 μg 26 CRM197 carrier protein, 100 μg polysorbate 80, 295 μg succinate buffer and 125 μg aluminum as aluminum phosphate adjuvant.
Immunogenicity and non-inferiority as measured by serotype-specific IgG
Percentage of infants with serotype-specific IgG concentrations ≥0.35 μg/mL
Time frame: 1 month after the booster dose
Immunogenicity and non-inferiority as measured by serotype-specific IgG GMC
Serotype-specific IgG GMCs
Time frame: 1 month after the booster dose
Solicited local and systemic adverse events after each dose
Frequency and severity of solicited local and systemic adverse events (AEs)
Time frame: within 30 min and 7 days after each dose
Unsolicited adverse events after each dose
Frequency and severity of unsolicited AEs
Time frame: within 30 days after each dose
Serious adverse events throughout the study
Frequency of serious AEs (SAEs)
Time frame: from dose 1 until 6 months after booster dose
Immune response to primary series as measured by serotype-specific IgG
Percentage of infants with pneumococcal serotype-specific IgG concentrations ≥0.35 µg/mL
Time frame: 1 month after the 2nd dose
Immune response to primary series as measured by serotype-specific IgG GMC
Serotype-specific IgG GMCs
Time frame: 1 month after the 2nd dose
Functional antibody responses as measured by serotype-specific OPA titer
Percentage of infants with serotype-specific OPA titer ≥1:8
Time frame: baseline, 1 month after the 2nd dose, before the booster dose, and 1 month after the booster dose
Functional antibody responses as measured by serotype-specific OPA geometric mean titers (GMTs)
Serotype-specific OPA geometric mean titers (GMTs)
Time frame: baseline, 1 month after the 2nd dose, before the booster dose, and 1 month after the booster dose
Immune persistence as measured by serotype-specific IgG
Percentage of infants with pneumococcal serotype-specific IgG concentrations ≥0.35 µg/mL
Time frame: 12-15 months of age, before the booster dose
Immune persistence as measured by serotype-specific IgG GMC
Serotype-specific IgG GMCs
Time frame: 12-15 months of age, before the booster dose
Exploratory_Non-interference
Percentage of infants with anti-diphtheria toxoid IgG concentrations ≥0.1 IU/mL
Time frame: 1 month after the 2nd dose
Exploratory_Non-interference
Percentage of infants with anti-tetanus toxoid IgG concentrations ≥0.1 IU/mL
Time frame: 1 month after the 2nd dose
Exploratory_Non-interference
Proportion of subjects with 4-fold increase in anti-pertussis IgG concentration
Time frame: 1 month after the 2nd dose with respect to baseline titers
Exploratory_Non-interference
Percentage of infants with anti Haemophilus influenzae type b (PRP) IgG concentration ≥0.15 µg/mL
Time frame: 1 month after the 2nd dose.
Exploratory_Non-interference
Percentage of infants with anti Hepatitis B surface antigen (hBsAg) IgG oncentrations ≥10 mIU/mL
Time frame: 1 month after the 2nd dose.
Exploratory_Non-interference
Percentage of infants with anti poliovirus types 1, 2 and 3 neutralizing antibody titers ≥1:8 measured
Time frame: 1 month after the 2nd dose.
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Mar 2025, 16 months after the start.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's planned 16 months is above that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Walvax Biotechnology Co., Ltd.